HRP20201315T1 - Pripravak koji sadrži hidrokortizon - Google Patents
Pripravak koji sadrži hidrokortizon Download PDFInfo
- Publication number
- HRP20201315T1 HRP20201315T1 HRP20201315TT HRP20201315T HRP20201315T1 HR P20201315 T1 HRP20201315 T1 HR P20201315T1 HR P20201315T T HRP20201315T T HR P20201315TT HR P20201315 T HRP20201315 T HR P20201315T HR P20201315 T1 HRP20201315 T1 HR P20201315T1
- Authority
- HR
- Croatia
- Prior art keywords
- preparation
- amount
- hydroxypropylmethylcellulose
- hydrocortisone
- sealing layer
- Prior art date
Links
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 title claims 16
- 229960000890 hydrocortisone Drugs 0.000 title claims 8
- 239000000203 mixture Substances 0.000 title claims 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 14
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 10
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 10
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 10
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 10
- 238000007789 sealing Methods 0.000 claims 9
- 235000019359 magnesium stearate Nutrition 0.000 claims 7
- 239000002245 particle Substances 0.000 claims 7
- 229940079593 drug Drugs 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 4
- 208000017515 adrenocortical insufficiency Diseases 0.000 claims 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 4
- 239000001856 Ethyl cellulose Substances 0.000 claims 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 3
- 210000004100 adrenal gland Anatomy 0.000 claims 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims 3
- 229920001249 ethyl cellulose Polymers 0.000 claims 3
- 230000000873 masking effect Effects 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 206010001367 Adrenal insufficiency Diseases 0.000 claims 2
- 208000005676 Adrenogenital syndrome Diseases 0.000 claims 1
- 208000008448 Congenital adrenal hyperplasia Diseases 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 206010020571 Hyperaldosteronism Diseases 0.000 claims 1
- 206010033165 Ovarian failure Diseases 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 208000010793 non-classic congenital adrenal hyperplasia Diseases 0.000 claims 1
- 201000004535 ovarian dysfunction Diseases 0.000 claims 1
- 231100000539 ovarian failure Toxicity 0.000 claims 1
- 229940037128 systemic glucocorticoids Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (14)
1. Farmaceutski pripravak prilagođen za oralnu primjenu, naznačen time što sadrži:
i) nosač, koji se uglavnom sastoji od čestica mikrokristalne celuloze u količini od 80-81% tež./tež. pripravka, gdje su navedene čestice promjera 350-500 µm;
ii) sloj lijeka, koji se uglavnom sastoji od djelotvorne količine hidrokortizona u količini od 0,64-0,66% tež./tež. pripravka i hidroksipropilmetilceluloze u količini od 0,64-0,66% tež./tež. pripravka koji sadrži nosač;
iii) brtveni sloj, koji se uglavnom sastoji od hidroksipropilmetilceluloze u količini od 14-16% tež./tež. pripravka i magnezijevog stearata u količini od 1,0-2,0% tež./tež. pripravka koji sadrži navedeni sloj lijeka; i
iv) sloj za prikrivanje okusa, koji se uglavnom sastoji od hidroksipropilmetilceluloze u količini od 0,14-0,16% tež./tež. pripravka, etilceluloze u količini od 0,58-0,62% tež./tež. pripravka i magnezijevog stearata u količini od 0,20-0,25% tež./tež. pripravka koji sadrži navedeni brtveni sloj.
2. Pripravak u skladu s patentnim zahtjevom 1, naznačen time što se navedena djelotvorna količina hidrokortizona kreće između otprilike 0,25 mg i 30 mg hidrokortizona po jedinici doze.
3. Pripravak u skladu s patentnim zahtjevom 2, naznačen time što je navedena djelotvorna količina hidrokortizona otprilike 0,25 mg, 0,50 mg, 1,00 mg, 2,00 mg, 5,00 mg, 10,00 mg, 20,00 mg ili 30,00 mg hidrokortizona po jedinici doze.
4. Pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što navedeni nosač sadrži čestice mikrokristalne celuloze, gdje se promjer navedenih čestica bira iz skupine koju čine: 350 µm, 375 µm, 400 µm, 425 µm, 450 µm, 475 µm i 500 µm.
5. Pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što brtveni sloj čini 15% tež./tež. ili 16% tež./tež. pripravka.
6. Pripravak u skladu s patentnim zahtjevom 5, naznačen time što brtveni sloj čini otprilike 15% tež./tež. pripravka.
7. Pripravak u skladu s patentnim zahtjevom 5, naznačen time što navedeni brtveni sloj sadrži otprilike 15% tež./tež. hidroksipropilmetilceluloze i otprilike 1,5% tež./tež. magnezijevog stearata u pripravku.
8. Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što sadrži:
i) nosač, koji se uglavnom sastoji od čestica mikrokristalne celuloze u količini od 80% tež./tež. pripravka, gdje su navedene čestice promjera od 350-500 µm;
ii) sloj lijeka, koji se uglavnom sastoji od hidrokortizona u količini od 0,64% tež./tež. pripravka i hidroksipropilmetilceluloze u količini od 0,64% tež./tež. pripravka koji sadrži navedeni nosač;
iii) brtveni sloj, koji se uglavnom sastoji od hidroksipropilmetilceluloze u količini od 14% tež./tež. pripravka i magnezijevog stearata u količini od 1,0% tež./tež. pripravka koji sadrži navedeni sloj lijeka; i
iv) sloj za prikrivanje okusa, koji se uglavnom sastoji od hidroksipropilmetilceluloze u količini od 0,14% tež./tež. pripravka, etilceluloze u količini od 0,58% tež./tež. pripravka i magnezijevog stearata u količini od 0,20% tež./tež. pripravka koji sadrži navedeni brtveni sloj.
9. Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što navedeni pripravak sadrži:
i) nosač, koji se sastoji od čestica mikrokristalne celuloze u količini od 81% tež./tež. pripravka;
ii) sloj lijeka, koji se sastoji od hidrokortizona u količini od 0,66% tež./tež. pripravka i hidroksipropilmetilceluloze u količini od 0,66% tež./tež. pripravka koji sadrži navedeni nosač;
iii) brtveni sloj, koji se sastoji od hidroksipropilmetilceluloze u količini od 15% tež./tež. pripravka i magnezijevog stearata u količini od 1,5% tež./tež. pripravka koji sadrži navedeni sloj lijeka; i
iv) sloj za prikrivanje okusa, koji se sastoji od hidroksipropilmetilceluloze u količini od 0,15% tež./tež. pripravka, etilceluloze u količini od 0,61% tež./tež. pripravka i magnezijevog stearata u količini od 0,23% tež./tež. pripravka koji sadrži navedeni brtveni sloj.
10. Pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačen time što je namijenjen upotrebi u liječenju insuficijencije nadbubrežne žlijezde kod subjekta.
11. Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 10, naznačen time što je insuficijencija nadbubrežne žlijezde uzrokovana stanjem kojeg se bira iz skupine koju čine: primarno ili sekundarno ili tercijarno zatajenje nadbubrežne žlijezde, prirođena hiperplazija nadbubrežne žlijezde, prirođena hiperplazija nadbubrežne žlijezde s kasnim početkom, zatajenje policističnih jajnika, aldosteronizam kojeg se može liječiti glukokortikoidima (GRA).
12. Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 11, naznačen time što je insuficijencija nadbubrežne žlijezde uzrokovana prirođenom hiperplazijom nadbubrežne žlijezde.
13. Pripravak namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 10 do 12, naznačen time što je subjekt pedijatrijski pacijent.
14. Pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačen time što je namijenjen upotrebi u kontrola insuficijencije nadbubrežne žlijezde kod pedijatrijskog subjekta koja se sastoji u primjeni djelotvorne količine pripravka u skladu s bilo kojim od patentnih zahtjeva 1 do 9 na subjektu kojem je potrebno liječenje insuficijencije nadbubrežne žlijezde najmanje jednom dnevno.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1308933.9A GB201308933D0 (en) | 2013-05-17 | 2013-05-17 | Paediatric composition |
| EP14727028.4A EP2978414B1 (en) | 2013-05-17 | 2014-05-12 | Composition comprising hydrocortisone |
| PCT/GB2014/051442 WO2014184525A1 (en) | 2013-05-17 | 2014-05-12 | Composition comprising hydrocortisone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201315T1 true HRP20201315T1 (hr) | 2020-11-27 |
Family
ID=48746932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201315TT HRP20201315T1 (hr) | 2013-05-17 | 2020-08-24 | Pripravak koji sadrži hidrokortizon |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US9649280B2 (hr) |
| EP (1) | EP2978414B1 (hr) |
| JP (1) | JP6371379B2 (hr) |
| KR (1) | KR102219919B1 (hr) |
| CN (1) | CN105120848B (hr) |
| AU (1) | AU2014267041B2 (hr) |
| BR (1) | BR112015028025B1 (hr) |
| CA (1) | CA2909060C (hr) |
| CY (1) | CY1123284T1 (hr) |
| DK (1) | DK2978414T3 (hr) |
| ES (1) | ES2813382T3 (hr) |
| GB (2) | GB201308933D0 (hr) |
| HK (1) | HK1214131A1 (hr) |
| HR (1) | HRP20201315T1 (hr) |
| HU (1) | HUE050917T2 (hr) |
| IL (1) | IL242275B (hr) |
| LT (1) | LT2978414T (hr) |
| MX (1) | MX2015015759A (hr) |
| PL (1) | PL2978414T3 (hr) |
| PT (1) | PT2978414T (hr) |
| RS (1) | RS60734B1 (hr) |
| RU (1) | RU2664678C2 (hr) |
| SI (1) | SI2978414T1 (hr) |
| WO (1) | WO2014184525A1 (hr) |
| ZA (1) | ZA201507210B (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201119985D0 (en) | 2011-11-19 | 2012-01-04 | Diurnal Ltd | Treatment of adrenal insufficiency |
| GB201308933D0 (en) | 2013-05-17 | 2013-07-03 | Diurnal Ltd | Paediatric composition |
| US20190180872A1 (en) * | 2017-12-12 | 2019-06-13 | International Business Machines Corporation | Second Opinion Decision Support Using Patient Electronic Medical Records |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE102022T1 (de) | 1990-08-30 | 1994-03-15 | Senju Pharma Co | Zusammensetzung zur kontrollierten abgabe von medikamenten. |
| EP0876142B1 (en) | 1996-01-16 | 2001-09-26 | Advanced Polymer Systems, Inc. | Topical delivery of drugs to the lower gastrointestinal tract |
| KR20040016202A (ko) * | 2002-08-16 | 2004-02-21 | 주식회사 제이알팜 | 쓴맛이 차폐된 히드로코르티손 경구용 약제 조성물 및 그제조방법 |
| JP2007533697A (ja) | 2004-04-22 | 2007-11-22 | デュオコート エービー | グルココルチコイド救急治療用の医薬組成物 |
| SE0401031D0 (sv) * | 2004-04-22 | 2004-04-22 | Duocort Ab | A new glucocorticoid replacement therapy |
| US9050249B2 (en) * | 2004-04-30 | 2015-06-09 | Astellas Pharma Inc. | Oral pharmaceutical compositions in timed-release particle form and fast-disintegrating tablets containing this composition |
| DE602005022499D1 (de) * | 2004-05-31 | 2010-09-02 | Almirall Sa | Kombinationen mit Antimuskarin-Wirkstoffen und PDE4-Hemmern |
| US20070281007A1 (en) * | 2004-08-27 | 2007-12-06 | Jacob Jules S | Mucoadhesive Oral Formulations of High Permeability, High Solubility Drugs |
| RU2290940C2 (ru) * | 2004-10-18 | 2007-01-10 | Государственное образовательное учреждение высшего профессионального образования "Нижегородская Государственная Медицинская академия" МЗ РФ (ГОУ ВПО НижГМА) | Средство для коррекции острой почечной недостаточности при токсическом гепаторенальном синдроме, индуцированном четыреххлористым углеродом, и способ коррекции острой почечной недостаточности при токсическом гепаторенальном синдроме, индуцированном четыреххлористым углеродом |
| AU2006309295B2 (en) * | 2005-06-03 | 2012-04-26 | Elan Pharma International Limited | Nanoparticulate acetaminophen formulations |
| WO2008126076A2 (en) * | 2007-04-11 | 2008-10-23 | Perrigo Israel Pharmaceuticals Ltd. | Low-dose mometasone formulations |
| GB0817120D0 (en) | 2008-09-19 | 2008-10-29 | Diurnal Ltd | Treatment of adrenal insufficiency |
| NZ602010A (en) | 2009-04-07 | 2013-11-29 | Duocort Pharma Ab | Improved glucocorticoid therapy |
| ES2683864T3 (es) * | 2009-10-01 | 2018-09-28 | Adare Pharmaceuticals, Inc. | Composiciones de corticosteroides administradas oralmente |
| MX2012006240A (es) * | 2009-12-02 | 2012-10-03 | Aptalis Pharma Ltd | Microcapsulas de fexofenadina y composiciones que contienen las mismas. |
| CA2799820A1 (en) | 2010-05-20 | 2011-11-24 | Duocort Pharma Ab | Posology and administration of glucocorticoid based compositions |
| GB201119985D0 (en) * | 2011-11-19 | 2012-01-04 | Diurnal Ltd | Treatment of adrenal insufficiency |
| GB201308933D0 (en) | 2013-05-17 | 2013-07-03 | Diurnal Ltd | Paediatric composition |
-
2013
- 2013-05-17 GB GBGB1308933.9A patent/GB201308933D0/en not_active Ceased
-
2014
- 2014-05-12 JP JP2016513431A patent/JP6371379B2/ja active Active
- 2014-05-12 WO PCT/GB2014/051442 patent/WO2014184525A1/en active Application Filing
- 2014-05-12 PL PL14727028T patent/PL2978414T3/pl unknown
- 2014-05-12 DK DK14727028.4T patent/DK2978414T3/da active
- 2014-05-12 LT LTEP14727028.4T patent/LT2978414T/lt unknown
- 2014-05-12 AU AU2014267041A patent/AU2014267041B2/en active Active
- 2014-05-12 RS RS20201002A patent/RS60734B1/sr unknown
- 2014-05-12 US US14/888,648 patent/US9649280B2/en active Active
- 2014-05-12 KR KR1020157035705A patent/KR102219919B1/ko active IP Right Grant
- 2014-05-12 BR BR112015028025-0A patent/BR112015028025B1/pt active IP Right Grant
- 2014-05-12 EP EP14727028.4A patent/EP2978414B1/en active Active
- 2014-05-12 CN CN201480021880.9A patent/CN105120848B/zh active Active
- 2014-05-12 PT PT147270284T patent/PT2978414T/pt unknown
- 2014-05-12 SI SI201431640T patent/SI2978414T1/sl unknown
- 2014-05-12 MX MX2015015759A patent/MX2015015759A/es unknown
- 2014-05-12 CA CA2909060A patent/CA2909060C/en active Active
- 2014-05-12 RU RU2015150303A patent/RU2664678C2/ru active
- 2014-05-12 HU HUE14727028A patent/HUE050917T2/hu unknown
- 2014-05-12 GB GB1516973.3A patent/GB2527233B/en active Active
- 2014-05-12 ES ES14727028T patent/ES2813382T3/es active Active
-
2015
- 2015-09-29 ZA ZA2015/07210A patent/ZA201507210B/en unknown
- 2015-10-26 IL IL242275A patent/IL242275B/en active IP Right Grant
-
2016
- 2016-02-23 HK HK16102011.3A patent/HK1214131A1/zh unknown
-
2020
- 2020-08-24 HR HRP20201315TT patent/HRP20201315T1/hr unknown
- 2020-08-27 CY CY20201100803T patent/CY1123284T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201315T1 (hr) | Pripravak koji sadrži hidrokortizon | |
| JP2017226708A5 (hr) | ||
| JP2014111603A5 (hr) | ||
| ECSP11011278A (es) | Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente. | |
| MX2020003381A (es) | Composicion para la prevencion o el tratamiento de enfermedades relacionadas con el factor de necrosis tumoral (tnf), que contiene un nuevo derivado como ingrediente activo, y metodo para inhibir la actividad del factor de necrosis tumoral (tnf) mediante el uso de la misma. | |
| GEP20166457B (en) | Low-oil pharmaceutical emulsion compositions comprising progestogen | |
| HRP20201627T1 (hr) | Postupak liječenja s tradipitantom | |
| HK1250714A1 (zh) | 雜芳基衍生物或其藥學上可接受的鹽、其製備方法以及包含其作為活性成分的用於預防或治療pi3激酶相關疾病的藥物組合物 | |
| SG10201901167SA (en) | Methods and compositions for treatment of attention deficit disorder | |
| HRP20221327T1 (hr) | Niraparib, abirateron acetat i prednizon za liječenje raka prostate | |
| EP4275677A3 (en) | Dosage regimen for a controlled-release pth compound | |
| HRP20200452T1 (hr) | Liječenje insuficijencije nadbubrežne žlijezde | |
| MX2018000546A (es) | Composiciones farmaceuticas que contienen celecoxib y tramadol. | |
| MX2016014696A (es) | Combinaciones de formoterol y budesonida para el tratamiento de enfermedad pulmonar obstructiva cronica. | |
| MX2018000084A (es) | Una composicion farmaceutica que comprende amlodipino, valsartan y rosuvastatina. | |
| RU2018146504A (ru) | Лечение внутрипеченочных холестатических заболеваний | |
| HRP20191491T1 (hr) | Biotin za liječenje demijelinizirajućih neuropatija | |
| RU2017112748A (ru) | Композиции онапристона пролонгированного действия и способы | |
| GB202004346D0 (en) | Preparation procedure for panax notoginseng medicinal liquor for oral administration for treating rheumatic ostalgia | |
| JP2016518439A5 (hr) | ||
| BR112015018895A2 (pt) | composição farmacêutica multiparticulada compreendendo uma multiplicidade de dois tipos de pelotas | |
| MX2018011293A (es) | Composicion farmaceutica de liberacion prolongada que comprende cisteamina o sal de la misma. | |
| PL408608A1 (pl) | Trwała stała kompozycja farmaceutyczna cytyzyny oraz sposób jej wytwarzania | |
| BR112014032264A8 (pt) | Composiçâo para tratamento ou prevençâo de doenças relacionadas á permeabilidade vascular, contendo imatinibe ou um sal farmaceuticamente aceitável respectivo como ingrediente ativo | |
| MX2019004736A (es) | Mini-tabletas de melatonina y metodos de fabricacion de las mismas. |